Celldex Therapeutics, Inc.
Celldex Therapeutics develops therapeutic antibodies for various diseases. Drug candidates target inflammatory, allergic, autoimmune, and other diseases. CDX-0159 is a Phase II monoclonal antibody that targets KIT receptor. The company collaborates with Yale University. Incorporated in 1983, Celldex is headquartered in New Jersey.
Overview
Strengths
- Conservative leverage: net debt is only 0.1x EBITDA.
Weaknesses
- No sign of a competitive advantage: return on invested capital (latest 0.0%) has been below its cost of capital of 7.6% in each of the last 6 years.
- Our discounted cash flow model finds no value to support the current price: free cash flow is negative.
- Shareholder dilution: the share count has grown by 12.1% a year over the last three years.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 6 of the last 6 years.
- Unstable profitability: operating margin ranged from -18,600% to -668% over the last 6 years, with operating losses in 6 of them.
Key Financial Data